Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation reports clinical oncology developments centered on Deep Cyclic Inhibitors, a category of cancer medicines the company is developing for durability, tolerability and combinability. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK being studied across MAPK pathway-driven tumors, including pancreatic cancer.
Recurring updates include survival and safety data from atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, molecular and circulating tumor DNA analyses tied to MAPK resistance mechanisms, and presentations at oncology meetings such as ASCO and AACR. Company news also covers financial results, R&D spending, pipeline strategy, regulatory-readiness activities and healthcare-conference presentations.
Immuneering (Nasdaq: IMRX) commented on the FDA’s newly approved second-line metastatic pancreatic cancer treatment and reiterated its focus on first-line patients. The company emphasized that its MEK inhibitor atebimetinib is being evaluated in the global, randomized, pivotal Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer, which is now enrolling and lists more than 35 sites on ClinicalTrials.gov.
Immuneering highlighted previously reported Phase 2a data in 55 first-line metastatic pancreatic cancer patients treated with atebimetinib 320 mg once daily plus modified gemcitabine/nab-paclitaxel. As of the April 24, 2026 cutoff, median overall survival was 17.3 months with median follow-up of 11.6 months; 84% of evaluable patients maintained or gained weight at three months. The only Grade 3 or higher treatment-related adverse events occurring in ≥10% of patients were anemia (16%) and neutropenia (18%), both described as chemotherapy-related.
Immuneering (Nasdaq: IMRX) reported second quarter 2026 results and business updates, highlighting its lead Deep Cyclic Inhibitor, atebimetinib. In a single-arm Phase 2a trial in first-line metastatic pancreatic cancer, atebimetinib plus modified gemcitabine/nab-paclitaxel showed a 17.3 month median overall survival in 55 patients, with 84% of evaluable patients weight stable or gaining weight at three months and limited high-grade treatment-related adverse event categories. A pivotal global Phase 3 trial, MAPKeeper 301, is underway with patients dosed and over 30 sites posted.
Immuneering ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities and expects its cash runway to extend into 2029. Q2 R&D expenses were $14.0 million and G&A expenses $5.0 million, leading to a net loss of $17.3 million, or $0.27 per share.
Immuneering (Nasdaq: IMRX) reported that peer‑reviewed data in Cancer Research describe atebimetinib’s differentiated mechanism and broad preclinical activity in RAS‑ and RAF‑mutant tumor models, including colorectal, lung, and melanoma. Atebimetinib simultaneously inhibited pERK and pMEK and resisted RAF‑mediated bypass signaling seen with other MEK inhibitors.
In head‑to‑head in vivo studies, atebimetinib achieved deeper, more durable tumor growth inhibition than FDA‑approved MEK inhibitor binimetinib while remaining well tolerated, with mice generally maintaining body weight within a 3–5% range. According to Immuneering, atebimetinib is being evaluated in the Phase 3 MAPKeeper 301 trial in metastatic pancreatic cancer, with a Phase 2 trial in RAS‑mutant NSCLC expected to start dosing in the second half of the year.
Immuneering (Nasdaq: IMRX) granted stock options as inducement awards tied to new hires effective July 16, 2026. New Chief Financial Officer Andrew Gengos received an option to purchase 650,000 Class A common shares at an exercise price of $4.78, equal to the July 16, 2026 Nasdaq closing price. The ten-year option, issued under the 2025 Employment Inducement Award Plan and approved by the Board, vests monthly over four years, becoming fully vested on the fourth anniversary of his start date.
On the same date, a non-executive employee received an option for 32,400 shares at the same exercise price, vesting 25% on July 16, 2027 and the remaining 75% in substantially equal monthly installments through July 16, 2030. Both grants were made under Nasdaq Rule 5635(c)(4) as material inducements to employment.
Immuneering (Nasdaq: IMRX) appointed Andrew Gengos as Chief Financial Officer, effective July 16, 2026. He previously served as CFO and Head of Corporate Development at Terns Pharmaceuticals, which Merck acquired for $6.7 billion.
Gengos will oversee financial strategy as Immuneering advances Phase 3 oncology candidate atebimetinib and its deep cyclic inhibitor pipeline.
Immuneering (Nasdaq: IMRX) has dosed the first patient in MAPKeeper 301, a global randomized open-label pivotal Phase 3 trial in first-line metastatic pancreatic cancer.
The study compares atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) versus standard GnP. Topline overall survival data are expected in mid-2028.
Immuneering (Nasdaq: IMRX) reported updated Phase 2a data for atebimetinib + mGnP in first-line metastatic pancreatic cancer at ASCO 2026. In 55 patients, median overall survival was 17.3 months (95% CI: 11.2, not reached), versus 8.5 months reported for gemcitabine/nab-paclitaxel in the pivotal MPACT study.
Median progression-free survival was 8.3 months, with 82% disease control rate and 36% confirmed overall response rate. Safety findings showed only two categories of Grade ≥3 treatment-related adverse events in ≥10% of patients, both chemotherapy related, and 84% of participants maintained or gained weight at three months.
The global randomized Phase 3 MAPKeeper 301 trial of atebimetinib plus mGnP versus standard gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer is actively recruiting, with first patient dosing expected in mid-2026 and topline readout targeted for mid-2028.
Immuneering (Nasdaq: IMRX) reported a 17.3‑month median overall survival (OS) in a Phase 2a trial of atebimetinib (IMM‑1‑104) plus modified gemcitabine/nab‑paclitaxel in first-line metastatic pancreatic cancer, based on 55 patients as of April 24, 2026.
Grade ≥3 treatment-related adverse events in ≥10% of patients were limited to chemotherapy‑related anemia (16%) and neutropenia (18%). Full data will be presented at ASCO on June 1, 2026, and support the recruiting Phase 3 MAPKeeper 301 trial. An investor call is scheduled for June 1, 2026, at 8:00 a.m. ET.
Immuneering (Nasdaq: IMRX) reported Q1 2026 results and oncology pipeline updates. Cash, cash equivalents and marketable securities were $198.6 million, with an expected runway into 2029. Q1 R&D expenses were $10.6 million and net loss was $13.5 million, or $0.21 per share.
The pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer is now recruiting, with first patient dosing planned by mid-2026. New survival data from 55 first-line pancreatic cancer patients on atebimetinib + mGnP will be presented at ASCO 2026.
Immuneering (Nasdaq: IMRX) will present updated Phase 2a survival data for atebimetinib plus mGnP in first-line pancreatic cancer at the 2026 ASCO Annual Meeting.
The oral presentation covers an expanded cohort of 55 first-line patients and is scheduled for June 1, 2026, 1:15 PM CDT, presented by Dr. Peter Vu.